Author:
Chawengrum Pornsuda,Luepongpatthana Natthaorn,Thongnest Sanit,Sirirak Jitnapa,Boonsombat Jutatip,Lirdprapamongkol Kriengsak,Keeratichamroen Siriporn,Kongwaen Patcharin,Montatip Phreeranat,Kittakoop Prasat,Svasti Jisnuson,Ruchirawat Somsak
Abstract
AbstractAnticopalic acid (ACP), a labdane type diterpenoid obtained from Kaempferia elegans rhizomes, together with 21 semi-synthetic derivatives, were evaluated for their cancer cytotoxic activity. Most derivatives displayed higher cytotoxic activity than the parent compound ACP in a panel of nine cancer cell lines. Among the tested compounds, the amide 4p showed the highest cytotoxic activity toward leukemia cell lines, HL-60 and MOLT-3, with IC50 values of 6.81 ± 1.99 and 3.72 ± 0.26 µM, respectively. More interestingly, the amide derivative 4l exhibited cytotoxic activity with an IC50 of 13.73 ± 0.04 µM against the MDA-MB-231 triple-negative breast cancer cell line, which is the most aggressive type of breast cancer. Mechanistic studies revealed that 4l induced cell death in MDA-MB-231 cells through non-apoptotic regulated cell death. In addition, western blot analysis showed that compound 4l decreased the phosphorylation of FAK protein in a concentration-dependent manner. Molecular docking simulations elucidated that compound 4l could potentially inhibit FAK activation by binding to a pocket of FAK kinase domain. The data suggested that compound 4l could be a potential FAK inhibitor for treating triple-negative breast cancer and worth being further investigated.
Funder
Royal Golden Jubilee Ph.D. Program, the National Research Council of Thailand
Thailand Science Research and Innovation (TSRI), Chulabhorn Research Institute
Publisher
Springer Science and Business Media LLC
Reference59 articles.
1. Rahmati, M., Nikmanesh, Y., Abshorshori, N. & Johari, B. Investigating the cytotoxic and anti-proliferative effects of trastuzumab on MDA-MB-453 and MDA-MB-468 breast cell lines with different levels of HER2 expression. J. Appl. Biotechnol. Rep. 7, 87–92 (2020).
2. WHO. Breast Cancer. https://www.who.int/news-room/fact-sheets/detail/breast-cancer (2021).
3. Iqbal, J. et al. Ursolic acid a promising candidate in the therapeutics of breast cancer: Current status and future implications. Biomed. Pharmacother. 108, 752–756. https://doi.org/10.1016/j.biopha.2018.09.096 (2018).
4. Liao, M. et al. Small-molecule drug discovery in triple negative breast cancer: Current situation and future directions. J. Med. Chem. 64, 2382–2418. https://doi.org/10.1021/acs.jmedchem.0c01180 (2021).
5. Mahmoud, R., Ordóñez-Morán, P. & Allegrucci, C. Challenges for triple negative breast cancer treatment: Defeating heterogeneity and cancer stemness. Cancers 14, 4280. https://doi.org/10.3390/cancers14174280 (2022).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献